[Durgical](https://durgical.com/en/) › [DurgiPedia](https://durgical.com/en/durgipedia/) › [Pharmacology](https://durgical.com/en/pharmacology/) › [TNF inhibitors](https://durgical.com/en/pharmacology/classes/tnf-inhibitors/) › Infliximab

[Pharmacology](https://durgical.com/en/pharmacology/) · [TNF inhibitors](https://durgical.com/en/pharmacology/classes/tnf-inhibitors/)

# Infliximab

A chimeric (part mouse) antibody against TNF-α given as an intravenous infusion, mainly for Crohn disease, ulcerative colitis and arthritis.

Updated 2026-11-01

- Class: [TNF inhibitors](https://durgical.com/en/pharmacology/classes/tnf-inhibitors/)
- Target: Tumour necrosis factor alpha (TNF-α)
- ATC code: L04AB02

◆**Tumour necrosis factor alpha (TNF-α)**Infliximab

ⓘ The figure shows human TNF-α bound to the Fab fragment of infliximab.

**Target in 3D:** Tumour necrosis factor alpha (TNF-α). PDB structure 4G3Y (RCSB PDB, public domain). [View the structure at RCSB PDB](https://www.rcsb.org/structure/4G3Y) · Drag to rotate · pinch to zoom

## Mechanism of action

Infliximab is a chimeric IgG1κ monoclonal antibody: human constant regions with mouse variable regions. It neutralises soluble and membrane TNF-α and prevents it from activating its receptors, which calms inflammation in the gut wall, the synovium and the skin. Its mouse portion makes antibodies against the drug more likely; these reduce its effect and raise infusion reactions, and methotrexate or azathioprine given with it lowers that risk.

- Chimeric antibody binds TNF-α
- TNF can no longer activate its receptors
- Gut, joint and skin inflammation settles
- Anti-drug antibodies can blunt the effect

## Pharmacokinetics

**Absorption**
Intravenous infusion only

**Distribution**
Stays mainly in the bloodstream

**Half-life**
About one to one and a half weeks

## Indications

- Crohn disease, including fistulising disease [Crohn disease →](https://durgical.com/en/conditions/crohn-disease/)
- Ulcerative colitis [Ulcerative colitis →](https://durgical.com/en/conditions/ulcerative-colitis/)
- Rheumatoid arthritis, together with methotrexate [Rheumatoid arthritis →](https://durgical.com/en/conditions/rheumatoid-arthritis/)
- Ankylosing spondylitis [Ankylosing spondylitis →](https://durgical.com/en/conditions/ankylosing-spondylitis/)
- Psoriatic arthritis [Psoriatic arthritis →](https://durgical.com/en/conditions/psoriatic-arthritis/)
- Severe plaque psoriasis [Psoriasis →](https://durgical.com/en/conditions/psoriasis/)

## Adverse effects

### Common

- Infusion reactions (fever, chills, itching, flushing)
- Upper respiratory infections and sinusitis
- Headache
- Nausea and abdominal pain

### Serious (rare, important)

- Serious infections (bacterial, viral, fungal and opportunistic) that can need hospital care or be fatal
- Reactivation of latent tuberculosis or hepatitis B
- Lymphoma and other cancers, including in children and young adults; hepatosplenic T-cell lymphoma in young people with inflammatory bowel disease
- New or worse heart failure
- Demyelinating disease (multiple sclerosis, optic neuritis, Guillain-Barré syndrome)
- Lupus-like syndrome; low blood counts
- Anaphylaxis and delayed serum-sickness-like reactions, especially after a long gap between infusions
- Liver injury

## Contraindications

- Moderate or severe heart failure at higher doses
- Previous severe hypersensitivity to infliximab or to mouse proteins
- Active serious infection, including active tuberculosis

## Key interactions

**Anakinra or abatacept**
More serious infections without added benefit; not combined.

**Live vaccines**
Risk of infection by the vaccine strain; avoided during treatment.

**Other immunosuppressants (glucocorticoids, methotrexate, azathioprine)**
Additive risk of infection; azathioprine or mercaptopurine with a TNF blocker has been linked to hepatosplenic T-cell lymphoma.

**Tocilizumab**
Added immunosuppression and infection risk.

## What is monitored

- Latent tuberculosis test before starting, and watch for active TB during and after treatment even if the test was negative
- Hepatitis B screening before starting
- Signs of infection at every visit
- Skin checks for cancer
- Vital signs before, during and after each infusion
- Liver tests

## Administration and safety

- Intravenous infusion only, given slowly over hours, through a set with an in-line low-protein-binding filter.
- The powder is reconstituted and diluted just before use and the infusion is started soon after.
- Not infused in the same line with other drugs.
- Emergency drugs for anaphylaxis are at hand; premedication may be ordered.
- Several biosimilars exist; the product is checked against the prescription.

## Nursing care

- Confirm that the latent TB test and hepatitis B screening are done (and treated if positive) before the first dose.
- Do not give the dose during an active infection; report fever, cough, night sweats or weight loss.
- Check that vaccines are up to date before starting; live vaccines are avoided during treatment.
- Ask about heart failure and neurological disease before starting.
- Watch for infusion reactions during and after the infusion; slow or stop it and call the team if they appear.

## Pregnancy and breastfeeding

It crosses the placenta and is found in the baby for months after birth; live vaccines for the exposed infant are delayed for at least six months.

## Memory aid

infliXImab: XI = mixed (chimeric) mouse-human → Infusion, Immunogenic, Infusion reactions.

## Test yourself

Think of the answer, then tap the question to see it.

## Why is methotrexate given together with infliximab in rheumatoid arthritis?

It improves the response and reduces antibodies against the chimeric antibody, which would otherwise lower its effect and raise infusion reactions.

## What equipment is required to give infliximab?

An intravenous set with an in-line, sterile, low-protein-binding filter; the infusion runs slowly over hours.

## In which heart condition is infliximab contraindicated at higher doses?

Moderate or severe heart failure.

[Add to my cards (3)](https://durgical.app/estudiar/?add=/en/pharmacology/infliximab/)

## Related drugs

- [Adalimumab](https://durgical.com/en/pharmacology/adalimumab/)
- [Etanercept](https://durgical.com/en/pharmacology/etanercept/)
- [Golimumab](https://durgical.com/en/pharmacology/golimumab/)
- [Certolizumab pegol](https://durgical.com/en/pharmacology/certolizumab-pegol/)

## Related conditions

- [Crohn disease](https://durgical.com/en/conditions/crohn-disease/)
- [Ulcerative colitis](https://durgical.com/en/conditions/ulcerative-colitis/)
- [Rheumatoid arthritis](https://durgical.com/en/conditions/rheumatoid-arthritis/)
- [Ankylosing spondylitis](https://durgical.com/en/conditions/ankylosing-spondylitis/)
- [Psoriatic arthritis](https://durgical.com/en/conditions/psoriatic-arthritis/)
- [Psoriasis](https://durgical.com/en/conditions/psoriasis/)

[← Back to the class: TNF inhibitors](https://durgical.com/en/pharmacology/classes/tnf-inhibitors/)

Educational content on how drugs work; not a prescribing guide and no substitute for a health professional's advice. No doses are given.

Sources: [Infliximab Injection: MedlinePlus Drug Information](https://medlineplus.gov/druginfo/meds/a604023.html) (MedlinePlus (U.S. National Library of Medicine), 2021); [DailyMed - INFLIXIMAB injection, powder, lyophilized, for solution](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b05c174f-832c-4321-b34f-2c4ad3742269) (DailyMed (U.S. National Library of Medicine), 2025); [Altered Immunocompetence | Vaccines & Immunizations | CDC](https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html) (Centers for Disease Control and Prevention (CDC), 2024); [ATCDDD - ATC/DDD Index](https://atcddd.fhi.no/atc_ddd_index/?code=L04AB02) (WHO Collaborating Centre for Drug Statistics Methodology, 2026).

## **Spotted a mistake?** We are always improving for the community. Tell us what is wrong and our team will review it. Report a mistake

Representative model, for educational purposes only.

---
Source: https://durgical.com/en/pharmacology/infliximab/
License: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Cite as: DurgiPedia (durgical.com), https://durgical.com/en/pharmacology/infliximab/